Enanta advances zelicapavir into late-stage trials
- Enanta Pharmaceuticals (NASDAQ:ENTA) is advancing its RSV antiviral, zelicapavir, into a registrational Phase 2b/3 trial for high-risk adults.
- The company's share price closed at $12.64 on June 17, 2026, marking a 4.72% daily gain ahead of the announcement.
- Enanta plans to initiate an additional Phase 2b trial for pediatric patients in the third quarter of 2026, with topline data for both studies expected in 2027.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced that it is advancing its lead candidate, zelicapavir, into a registrational Phase 2b/3 clinical trial for adults at high risk of severe RSV infection.
The decision follows a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), establishing a clear regulatory pathway for the drug.
The company estimates that an effective oral RSV antiviral for children and high-risk adults represents a global market opportunity exceeding $2 billion.
In addition to the adult study, Enanta will initiate a Phase 2b trial in pediatric patients during the third quarter of 2026, conducted in collaboration with the Penta Foundation.
The biotechnology firm, based in Watertown, Massachusetts, continues to focus its research and development on small molecule drugs for viral and immunological diseases.
The company remains positioned as a leader in RSV research, aiming to deliver what could potentially be the first antiviral therapy available for patients suffering from the virus.
